一项2026年的研究发现,AMD3100是一种经批准的药物,它通过扭转他们被排除在肿瘤之外的趋势,帮助免疫细胞感染罕见肝癌。 A 2026 study found AMD3100, an approved drug, helps immune cells attack rare liver cancer by reversing their exclusion from tumors.

2026年2月17日,胃肠病学杂志的一项研究显示,FDA批准的AMD3100药物可以克服纤维瘤免疫疗法抵抗性,这是影响年轻人的罕见肝癌. A February 17, 2026, study in Gastroenterology reveals that AMD3100, an FDA-approved drug, may overcome immunotherapy resistance in fibrolamellar carcinoma, a rare liver cancer affecting young people. 研究发现肿瘤微环境在纤维地区捕捉T型免疫细胞,防止癌症袭击。 The research found tumor microenvironments trap immune T cells in fibrous regions, preventing cancer attack. AMD3100扭转了T细胞的排斥,使T细胞能够接触肿瘤。 AMD3100 reversed this T-cell exclusion, enabling T cells to reach tumors. 结合免疫检查站抑制剂,它大大增加了患者样本中的肿瘤细胞死亡。 Combined with immune checkpoint inhibitors, it significantly increased tumor cell death in patient samples. 由于AMD3100已经得到批准,对这种癌症的临床试验可以很快开始。 Because AMD3100 is already approved, clinical trials for this cancer could begin quickly.